Jyong Biotech (NASDAQ:MENS) Stock Price Up 2.7% – Should You Buy?

Jyong Biotech Ltd. (NASDAQ:MENS)’s stock price rose 2.7% on Thursday . The company traded as high as $2.33 and last traded at $2.30. 14,428 shares were traded during trading, a decline of 61% from the average session volume of 37,089 shares. The stock had previously closed at $2.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Jyong Biotech Stock Up 3.0%

The company has a fifty day moving average of $2.16 and a 200 day moving average of $2.12.

Hedge Funds Weigh In On Jyong Biotech

Hedge funds have recently modified their holdings of the stock. Man Group plc purchased a new stake in shares of Jyong Biotech in the fourth quarter worth about $56,000. BNP Paribas Financial Markets purchased a new stake in shares of Jyong Biotech during the 3rd quarter valued at about $67,000. Millennium Management LLC grew its position in Jyong Biotech by 209.4% in the fourth quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock worth $159,000 after acquiring an additional 27,245 shares in the last quarter. Geode Capital Management LLC raised its position in Jyong Biotech by 19.6% during the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock valued at $254,000 after purchasing an additional 10,538 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Jyong Biotech during the 4th quarter valued at approximately $275,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.